Novel Alpha Glucan GI Tolerability Study (Loris Chronic)

This study will be randomized, double blind, placebo-controlled, single-center, and 3x3 crossover in design.

Eligible participants will be randomized to receive the below products in single dose and in different random sequence, as determined by the randomization system:

• novel alpha glucan (80 g/day)
• novel alpha glucan (180 g/day)
• glucose syrup (180 g/day)

Inclusion criteria

• Male or female participant,
• Healthy status (based on anamnesis),
• Age between 18 and 65 years,
• Body mass index (BMI) between 18.5 and 29.9 kg/m2,
• Able to understand and sign informed consent form,
• Having a smartphone with Android or iOS version compatible with Patient Cloud application

Exclusion criteria

• Fasting plasma glucose higher or equal to 6,1 mmol /L at screening,
• Type I and type 2 diabetes,
• Pregnant or lactating women,
• Known food allergy or intolerance to test products,
• Treatment with anorectic drugs, glucose-lowering drugs, steroids, medications known to affect glucose metabolism and/or gastric motility, or any condition known to affect gastro-intestinal integrity and food absorption,
• Colonoscopy, irrigoscopy or other bowel cleansing procedures four weeks prior the test,
• Any concomitant medication potentially interfering with study procedures and assessment: such as antibiotics, antiacids, or other medications impacting transit time,
• Major medical/surgical event in the last 3 months potentially interfering with study procedures and assessments,
• Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory bowel disease, diverticular diseases, colon cancer), or history of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average or chronic or recurrent diarrhea with spontaneous bowel movements more often than 3 times daily,
• Recent episode of an acute gastrointestinal illness,
• Habitual consumption of more than four servings per day of high-fiber foods or extreme dietary habits (e.g. very low carbohydrate diet),
• Ongoing or recent weight loss interventions (e.g. dietary weight loss programs),
• Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer,
• Score of "severe" symptom for any of the symptoms included in the gastrointestinal symptom questionnaire,
• Volunteer who cannot be expected to comply with the protocol,
• Family or hierarchical relationships with Clinical Innovation Lab team.